Outsmarting the world's most resistant pathogens.
Fedora develops new antibiotics for the infections that defeat today's drugs. We target the multi-drug-resistant bacteria the rest of the industry walked away from.
Founded in 2011 to take on a problem the industry walked away from.
Large pharmaceutical companies stepped back from antibiotics. Fedora stepped in. From Edmonton, Alberta, our scientists have discovered anti-infectives that doctors still prescribe today, and we put that track record behind the next generation of candidates.
Four decades of antibiotic discovery.
From the invention of tazobactam to today's first-in-class candidate, FPI-2119.
Antimicrobial resistance is outpacing our medicines.
AMR is one of the top ten global public health threats. As bacteria evolve to resist the antibiotics modern medicine depends on, the world urgently needs new ones — the problem Fedora exists to solve.
We disarm the enzymes that make antibiotics fail.
Bacteria make beta-lactamase enzymes that destroy beta-lactam antibiotics: penicillins, cephalosporins, and carbapenems. Those three classes are over 60% of every antibiotic prescribed. Fedora's inhibitors shut the enzymes down and put the drugs back to work.
Resistant bacteria produce beta-lactamases that neutralize front-line antibiotics.
Nacubactam blocks those enzymes through several mechanisms at once.
Paired with meropenem, it works even against carbapenem-resistant strains.
Nacubactam
A Phase 3-ready beta-lactamase inhibitor with broad-spectrum activity in combination with beta-lactam antibiotics.
A deep bench against drug-resistant infection.
One Phase 3-ready asset, one current lead in development, and earlier-stage candidates behind them.
A team that has brought antibiotics to market.
Fedora's scientists have developed anti-infectives now in clinical use — the team behind two globally marketed antibiotics, tazobactam and nacubactam.
The latest from Fedora.
In April 2026, Fedora presented its current lead, FPI-2119, in Munich: eight posters and two talks on its activity against resistant Gram-negative infections.
FPI-2119 takes center stage at ESCMID Global 2026
Eight posters and two talks on how FPI-2119 kills antibiotic-resistant bacteria.
Read more → Apr 19, 2026Presentations highlight safety & potent activity of FPI-2119
Activity data against Gram-negative community and hospital-acquired infections, across eight posters.
Read more → Apr 9, 2026Fedora to showcase its antibiotic candidate at ESCMID 2026
Preclinical findings on FPI-2119, presented in Munich.
Read more →Let's get the next antibiotic to patients.
Fedora seeks partnerships and licensing agreements with industry and academia to move the pipeline forward.
Start a conversation →
